At a glance
ClinicalIndex Comparison RecordN/ACompleted· 193 enrolled
Drug / intervention
Participant completed survey +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LUNELORD: A Descriptive, Prospective Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and QoL of Patients With LUpus NEphritis and Long-term ORgan Damage
In Brief
An observational study evaluating Participant completed survey and Medical chart review for Systemic Lupus Erythematosus. Completed, enrolled 193 participants across 6 sites in 4 countries.
Detailed Summary
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesKuwait, Oman, Qatar, United Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedJul 2021
Enrollment StartSep 2021
Primary CompletionOct 2024
TodayJul 2026
First PostedJul 21, 2021
Enrollment StartSep 14, 2021
Primary CompletionOct 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.9 years ago
Interventions
Participant completed surveyother
Participants will be required to complete the participant survey.
Medical chart reviewother
Data will be collected from medical charts of participants.